Research backs telmisartan use

The angiotensin receptor blocker telmisartan can reduce the risk of cardiovascular death in high-risk patients who are intolerant to ACE inhibitors, according to Canadian research.

This latest study builds on research from the ONTARGET trial, which showed that telmisartan was as effective as ramipril at cutting CVD risk and better tolerated (GP, 11 April).

The TRANSCEND study found that telmisartan (80mg daily) cut risk of cardiovascular death in high-risk patients by 13 per cent after 56 months.

Primary Care Cardiovascular Society member Dr Sarah Jarvis said: 'We now have evidence that telmisartan protects against heart attack, stroke and cardiovascular death.'

Lancet Online 2008.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus